sEMG Biofeedback for Episodic Migraines: A Pilot Randomized Clinical Trial

IF 2.2 3区心理学 Q2 PSYCHOLOGY, CLINICAL

Applied Psychophysiology and Biofeedback Pub Date : 2024-01-27 DOI:10.1007/s10484-023-09615-0

Asimina Lazaridou, Myrella Paschali, Carolyn Bernstein, Marie Curiel, Sara Moore, Robert R. Edwards

{"title":"sEMG Biofeedback for Episodic Migraines: A Pilot Randomized Clinical Trial","authors":"Asimina Lazaridou, Myrella Paschali, Carolyn Bernstein, Marie Curiel, Sara Moore, Robert R. Edwards","doi":"10.1007/s10484-023-09615-0","DOIUrl":null,"url":null,"abstract":"<div>The aim of this study was to assess the feasibility and potential effectiveness of a 6-week virtual sEMG biofeedback intervention for patients with episodic migraines. Patients with episodic migraines were randomized to treatment with a novel surface EMG (sEMG) at-home biofeedback device or a treatment as usual control group; they completed validated baseline and post-intervention assessments of migraine related disability (migraine-specific quality of life, anxiety and depression). Participants also underwent a series of Quantitative Sensory Testing (QST) procedures referring to several different tests that quantitatively assess responses to mechanical stimuli during two separate visits (baseline and post intervention). No adverse events were reported during the study. Compared to the treatment as usual comparison group, patients in the sEMG biofeedback group reported lower migraine disability (p < 0.05). Compared to baseline, participants in the sEMG biofeedback group demonstrated statistically significant reductions in anxiety (p < 0.01), and significant increases in quality of life (p < 0.001), and significant decreases in temporal summation (p < 0.05) assessed by QST. No significant changes were observed in any of the outcomes in the control comparison group (p > 0.05). No significant changes were observed in migraine frequency in either of the two groups (p > 0.05). In addition, mediation analyses revealed that changes in migraine related quality of life mediated group effects on changes in migraine disability. Virtual sEMG biofeedback shows promise as a potential therapy for reducing disability, anxiety and depression and improving quality of life in individuals with episodic migraines. These results demonstrate the feasibility of a digital intervention for migraines and set the basis for conducting a future, larger scale randomized controlled trial to confirm these preliminary findings.</div>","PeriodicalId":47506,"journal":{"name":"Applied Psychophysiology and Biofeedback","volume":"49 2","pages":"271 - 279"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Psychophysiology and Biofeedback","FirstCategoryId":"102","ListUrlMain":"https://link.springer.com/article/10.1007/s10484-023-09615-0","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this study was to assess the feasibility and potential effectiveness of a 6-week virtual sEMG biofeedback intervention for patients with episodic migraines. Patients with episodic migraines were randomized to treatment with a novel surface EMG (sEMG) at-home biofeedback device or a treatment as usual control group; they completed validated baseline and post-intervention assessments of migraine related disability (migraine-specific quality of life, anxiety and depression). Participants also underwent a series of Quantitative Sensory Testing (QST) procedures referring to several different tests that quantitatively assess responses to mechanical stimuli during two separate visits (baseline and post intervention). No adverse events were reported during the study. Compared to the treatment as usual comparison group, patients in the sEMG biofeedback group reported lower migraine disability (p < 0.05). Compared to baseline, participants in the sEMG biofeedback group demonstrated statistically significant reductions in anxiety (p < 0.01), and significant increases in quality of life (p < 0.001), and significant decreases in temporal summation (p < 0.05) assessed by QST. No significant changes were observed in any of the outcomes in the control comparison group (p > 0.05). No significant changes were observed in migraine frequency in either of the two groups (p > 0.05). In addition, mediation analyses revealed that changes in migraine related quality of life mediated group effects on changes in migraine disability. Virtual sEMG biofeedback shows promise as a potential therapy for reducing disability, anxiety and depression and improving quality of life in individuals with episodic migraines. These results demonstrate the feasibility of a digital intervention for migraines and set the basis for conducting a future, larger scale randomized controlled trial to confirm these preliminary findings.

Abstract Image

查看原文本刊更多论文

sEMG 生物反馈治疗发作性偏头痛：试验性随机临床试验。

本研究旨在评估对发作性偏头痛患者进行为期 6 周的虚拟 sEMG 生物反馈干预的可行性和潜在有效性。发作性偏头痛患者被随机分配到使用新型表面肌电图（sEMG）居家生物反馈设备治疗组或照常治疗对照组；他们完成了偏头痛相关残疾（偏头痛特定生活质量、焦虑和抑郁）的验证基线和干预后评估。参与者还接受了一系列定量感官测试（QST）程序，这些测试指的是在两次单独访问（基线访问和干预后访问）期间对机械刺激的反应进行定量评估的几种不同测试。研究期间未报告任何不良事件。与常规治疗对比组相比，sEMG 生物反馈组患者的偏头痛致残率较低（P 0.05）。两组患者的偏头痛频率均无明显变化（P>0.05）。此外，中介分析表明，偏头痛相关生活质量的变化对偏头痛残疾变化的群体效应具有中介作用。虚拟 sEMG 生物反馈疗法有望减少发作性偏头痛患者的残疾、焦虑和抑郁，并改善其生活质量。这些结果证明了对偏头痛进行数字干预的可行性，并为今后开展更大规模的随机对照试验以证实这些初步研究结果奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Psychophysiology and Biofeedback PSYCHOLOGY, CLINICAL-

CiteScore

5.30

自引率

13.30%

发文量

期刊介绍： Applied Psychophysiology and Biofeedback is an international, interdisciplinary journal devoted to study of the interrelationship of physiological systems, cognition, social and environmental parameters, and health. Priority is given to original research, basic and applied, which contributes to the theory, practice, and evaluation of applied psychophysiology and biofeedback. Submissions are also welcomed for consideration in several additional sections that appear in the journal. They consist of conceptual and theoretical articles; evaluative reviews; the Clinical Forum, which includes separate categories for innovative case studies, clinical replication series, extended treatment protocols, and clinical notes and observations; the Discussion Forum, which includes a series of papers centered around a topic of importance to the field; Innovations in Instrumentation; Letters to the Editor, commenting on issues raised in articles previously published in the journal; and select book reviews. Applied Psychophysiology and Biofeedback is the official publication of the Association for Applied Psychophysiology and Biofeedback.